Guidelines Updated for Use of Antiplatelet Therapy for Atherosclerotic CVD
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 19, 2023 (HealthDay News) -- In a guideline update issued by the Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology and published online Oct. 28 in the Canadian Journal of Cardiology, new recommendations are presented regarding the use of antiplatelet therapy (APT) for the prevention of atherosclerotic cardiovascular disease.
Kevin R. Bainey, M.D., from the Mazankowski Alberta Heart Institute at the University of Alberta in Edmonton, Canada, and colleagues updated guidelines for the use of APT for primary and secondary prevention of atherosclerotic cardiovascular disease.
The guidelines provide recommendations relating to the use of acetylsalicylic acid in the primary prevention of atherosclerotic cardiovascular disease; duration of dual APT (DAPT) after percutaneous coronary intervention (PCI) in patients with a high risk for bleeding; choice of potent DAPT (P2Y12 inhibitor) for patients presenting with an acute coronary syndrome (ACS) and possible DAPT de-escalation strategies after PCI; choice and duration of DAPT in patients with ACS who are treated medically, without revascularization; and DAPT pretreatment before coronary angiography. In addition, recommendations also address perioperative and longer-term APT management for those who need coronary artery bypass grafting surgery, as well as the use of APT for patients with atrial fibrillation who require oral anticoagulation after PCI or ACS with medical management.
"We really focus on individuals and determining their cardiovascular risk, their risk of bleeding, and then tailoring their antiplatelet therapy to maximize the outcomes for them," Bainey said in a statement. "So, it's really taking it to a different level; we're the first in the world to endorse a shared decision-making model, engaging the person who is at risk together with their doctor."
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Overall Burden of CVD Remained High in United Kingdom in 2000 to 2019
THURSDAY, June 27, 2024 -- The overall burden of cardiovascular disease (CVD) remained high during 2000 to 2019 in the United Kingdom, according to a study published online June...
hs-cTnT Linked to MACE, Mortality in Rheumatoid Arthritis
THURSDAY, June 27, 2024 -- For patients with rheumatoid arthritis (RA), a detectable level of high-sensitivity cardiac troponin T (hs-cTnT) is associated with increased risk of...
Childhood Risk Factors Directly Tied to Adult Cardiovascular Disease
MONDAY, June 24, 2024 -- Childhood risk factors are associated both directly and indirectly to adult cardiovascular disease (CVD), according to a study published online June 24...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.